NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 13 July 2021

**Location:** Via Zoom Teleconference

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all Items
2. Dr Peter Selby (Vice Chair) Present for all Items
3. Dr Alex Cale Present for all Items
4. Dr Prithwiraj Das Present for all Items
5. Dr David Foreman Present for all Items
6. Dr Rob Forsyth Present for all Items
7. Dr Natalie Hallas Present for all Items
8. John Hampson Present for all Items
9. Dr Nigel Langford Present for all Items
10. Kirandip Moyo Items 1 to 5.1.3
11. Dr Mudasar Mushtaq Items 1 to 4.2.2
12. Dr Richard Nicholas Present for all Items
13. Ugochi Nwulu Present for all Items
14. Stella O’Brien Present for all Items
15. Professor Andrew Renehan Present for all Items
16. Professor Matthew Stevenson Present for all Items
17. Professor Paul Tappenden Items 1 to 4.2.2

NICE staff present

Helen Knight, Programme Director Items 5 to 5.2.2

Ross Dent, Associate Director Present for all Items

Louise Jafferally, Project Manager Present for all Items

Sally Doss, Health Technology Assessment Adviser Items 1 to 4.2.2

Alexandra Filby, Health Technology Assessment Adviser Items 5 to 5.2.2

Fatima Chunara, Health Technology Assessment Analyst Items 1 to 4.2.2

Abitha Senthinathan, Health Technology Assessment Analyst Items 5 to 5.2.2

Catherine Spanswick, Health Technology Assessment Analyst Items 1 to 4.2.2

Edgar Masanga, Business Analyst, RIA Items 1 to 4.2.2

Philip Williams, Business Analyst, RIA Items 5 to 5.2.2

Emilene Coventry, Senior Medical Editor Items 1 to 4.2.2

Ria Skelton Senior Medical Editor Items 5 to 5.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 1 to 4.2.2

Thomas Strong, Technical Adviser, Commercial Risk Assessment Items 5 to 5.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 5 to 5.2.2

Stevie Okoro, Technical Analyst, Commercial Risk Assessment Items 5 to 5.2.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Sandra Robinson, Assistant Project Manager, Corporate Office Items 5 to 5.1.3

Nick Cunningham, Coordinator, Corporate Office Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all Items

Iain Cannell, Administrator, TA Present for all Items

Hollie Kemp, Apprentice, COT Items 1 to 4.2.2

Daniel Greenwood, Assistant Administrator, COT Items 5 to 5.2.2

External review group representatives present

Ewen Cummins, Warwick Evidence Items 1 to 4.1.3

Daniel Gallacher, Warwick Evidence Items 1 to 4.1.3

Toyin Lamina, Warwick Evidence Items 1 to 4.1.3

Emma Hock, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Paul Tappenden, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Clinical & patient experts present

Professor Peter Clark, National Clinical lead for Cancer drugs, NHS England, Items 1 to 4.2.2

Dr Kate Cwyranski, Consultant Haematologist, clinical expert nominated by NCRI High grade Lymphoma Group, Items 1 to 4.1.3

Dr Christopher Fox, Consultant Haematologist, clinical expert nominated by Bristol Myers Squibb Pharmaceutical Ltd, Items 1 to 4.1.3

Mark Hunter, Patient expert nominated by Lymphoma Action, Items 1 to 4.1.3

Dr Anne-Marie Childs, Consultant Paediatric Neurologist, clinical expert nominated by Muscular Dystrophy UK and Roche Products Ltd, Items 5 to 5.1.3

Lucy Frost, Patient expert nominated by TreatSMA, Items 5 to 5.1.3

Dr Channa Hewamadduma, Consultant neurologist, clinical expert nominated by Muscular Dystrophy UK, Items 5 to 5.1.3

Fiona Marley, NHS Commissioning expert, NHS England, Items 5 to 5.1.3

Liz Ryburn, Patient expert nominated by SMA UK and Muscular Dystrophy UK, Items 5 to 5.1.3

Andi Thornton, Patient expert nominated by TreatSMA, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 16 June 2021

### Appraisal of lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (ID1444)

* 1. Part 2a – Closed session (no public observers)
		1. The chair welcomed the invited clinical and patient experts, external review group representatives, the national clinical lead for cancer drugs and company representatives from Celgene, a BMS company.
		2. The chair asked all committee members, clinical and patient experts, external group representatives, the national clinical lead for cancer drugs and NICE staff present to declare any relevant interests in relation to the Item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Roche for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Nominated clinical expert Dr Kate Cwynarski declared financial interests as she has received consultancy, advisory and speaker fees from Roche, Takeda, Celgene, Atara, Gilead, KITE, Janssen, Incyte, Gilead, and has also received conference and travel support from Roche, Takeda, KITE, Janssen and BMS.
* It was agreed that her declarations would not prevent Dr Cwynarski from providing expert advice to the committee.
* Nominated clinical expert Dr Christopher Fox declared financial interests as he has received consultancy and advisory fees from Celgene, a BMS company.
* It was agreed that his declarations would not prevent Dr Fox from providing expert advice to the committee.
	+ 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by John Hampson, Professor Matt Stevenson, and Stella O’Brien.
	1. Part 2b – Closed session (company representatives, clinical and patient experts and external review group representatives were asked to leave the meeting.)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). in line with their decisions.

### Appraisal of risdiplam for treating spinal muscular atrophy in children and adults (ID1631)

* 1. Part 1 – Open session
		1. The chair Professor Stephen O’Brien welcomed the invited clinical and patient experts, external review group representatives, NHS commissioning expert, members of the public and company representatives from Roche products.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives, NHS commissioning expert and NICE staff present to declare any relevant interests in relation to the Item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards with Roche for treatment in an unrelated area (MS).
* It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* Committee member Dr Robert Forsyth declared non-financial professional interests as he is a paediatric neurologist and whilst not directly involved in the care of neuromuscular diseases (such as SMA) in children, he has made the diagnosis of SMA in children. He also knows many if not most of the paediatric neurologists caring for SMA in the UK professionally. He was also asked to act as a non-voting member/advisor for the nusinersin MAOC.
* It was agreed that his declarations would not prevent Dr Forsyth from participating in this section of the meeting.
* Committee member Professor Matthew Stevenson declared a non-financial professional interest as ScHARR-TAG carried out the work for risdiplam and he had peer reviewed the work.
* It was agreed that his declaration would not prevent Professor Stevenson from participating in discussions in this section of the meeting however he is prevented from being a voting committee member if a vote is required to determine the outcome of this appraisal.
* Nominated clinical expert Dr Anne-Marie Childs declared financial and professional interests as she has received professional fees for contribution to advisory boards for Roche, Biogen and Avexis in relation to drug development in SMA, she is a PI for iSMAC and REACH in Leeds Children’s Hospital and is also a medical trustee for SMA UK and a member of the NHSE clinical panel supporting the MAA for nusinersen.
* It was agreed that her declarations would not prevent Dr Childs from providing expert advice to the committee.
* Nominated clinical expert Dr Channa Hewamadduma declared financial and professional interests as he has received payment from Biogen for delivering a talk on nusinersen treatment in adult patients. He has also received payment for being on an advisory board of clinical experts for critical analysis of Roche clinical trial dataset, has taken part in two 'one off' advisory roles to Roche in critical appraisal of evidence for risdiplam and Roche had organised for him to attend the SMA Europe meeting in Feb 2020. Roche provided him with a travel grant which enabled him to attend the SMA conference and he has given a talk on nusinersen in adult SMA patients at a webinar held by Biogen and he is developing PROMS for adult SMA patients in collaboration with Biogen. In addition to interests declared at the previous meeting for this appraisal in May 2021 Dr Hewamadduma added that he had chaired a webinar on 24th of June 2021 organised by Biogen on sharing best practice in setting up adult nusinersen services across UK
* It was agreed that his declaration would not prevent Dr Hewamadduma from providing expert advice to the committee.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 - Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 11 August 2021 and will start promptly at 9.30am.